137 related articles for article (PubMed ID: 36270831)
21. Management of stage I occult uterine leiomyosarcoma: effects of morcellation, second-look surgery, and adjuvant treatments on survival.
Yang J; Yang J; Cao D; Pan L; Wu M; Xiang Y
Ann Transl Med; 2022 Jan; 10(2):127. PubMed ID: 35282058
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
[TBL] [Abstract][Full Text] [Related]
23. Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study.
van den Haak L; de Kroon CD; Warmerdam MI; Siebers AG; Rhemrev JP; Nieboer TE; Jansen FW
Arch Gynecol Obstet; 2019 Jan; 299(1):159-165. PubMed ID: 30498966
[TBL] [Abstract][Full Text] [Related]
24. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
25. Uterine leiomyosarcoma: an updated series.
Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
[TBL] [Abstract][Full Text] [Related]
26. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
27. An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center.
Solmaz U; Dereli L; Demirtaş GS; Ekin A; Mat E; Gezer C; Solmaz Hasdemir P; Sayhan S; Sancı M; Aşkar N
Turk J Obstet Gynecol; 2015 Sep; 12(3):158-163. PubMed ID: 28913061
[TBL] [Abstract][Full Text] [Related]
28. Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Tokunaga H; Takahashi F; Yamamoto H; Honda T; Watanabe T; Shoji T; Sugiyama T; Yamada H; Tando T; Yoshinaga K; Kagabu S; Otsuki T; Kin S; Yokoyama Y; Wagatsuma S; Sato K; Sato H; Oishi T; Yoshida Y; Hayasaka T; Matsui T; Imai N; Nishigori H; Shimokawa H; Yaegashi N; Watanabe Y
Int J Clin Oncol; 2017 Jun; 22(3):541-547. PubMed ID: 28188392
[TBL] [Abstract][Full Text] [Related]
29. Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment.
Sanfilippo R; Sbaraglia M; Fabbroni C; Croce S; Ray-Coquard I; Guermazi F; Paolini B; Blanc-Durand F; Lecesne A; Chiappa V; Dei Tos AP; Casali PG
Clin Cancer Res; 2023 Nov; 29(22):4679-4684. PubMed ID: 37699075
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma.
Baek MH; Park JY; Park Y; Kim KR; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e30. PubMed ID: 29533018
[TBL] [Abstract][Full Text] [Related]
32. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
Cybulska P; Sioulas V; Orfanelli T; Zivanovic O; Mueller JJ; Broach VA; Long Roche KC; Sonoda Y; Hensley ML; O'Cearbhaill RE; Chi DS; Alektiar KM; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2019 Aug; 154(2):333-337. PubMed ID: 31200927
[TBL] [Abstract][Full Text] [Related]
33. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.
Singh N; Al-Ruwaisan M; Batra A; Itani D; Ghatage P
J Obstet Gynaecol Can; 2020 Dec; 42(12):1483-1488. PubMed ID: 32900677
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
[TBL] [Abstract][Full Text] [Related]
35. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
36. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
37. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
38. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
[TBL] [Abstract][Full Text] [Related]
39. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
